Pirfenidone increases survival in patients with idiopathic pulmonary fibrosis
Pirfenidone treatment increased 3-year survival rates in patients who have idiopathic pulmonary fibrosis (IPF) and resulted in a 30% survival benefit compared with patients who have not been treated with antifibrotic agents, according to a retrospective observational intention-to-treat study reported online Nov. 23, 2018 in BMC Pulmonary Medicine.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies